Article Text

other Versions

PDF
Letter
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
  1. N Vande Casteele1,
  2. V Ballet2,
  3. G Van Assche2,
  4. P Rutgeerts2,
  5. S Vermeire2,
  6. A Gils1
  1. 1Laboratory for Pharmaceutical Biology, Department of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
  2. 2Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
  1. Correspondence to A Gils, Laboratory for Pharmaceutical Biology, Department of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Herestraat 49 box 824, Leuven 3000, Belgium; ann.gils{at}pharm.kuleuven.be

Statistics from Altmetric.com

We read with great interest the recent article by Ben-Horin et al which concludes that the measurement of trough levels of infliximab (TLI) combined with the measurement of antibodies to infliximab (ATI) is highly correlated with the clinical response to the therapeutic.1

Infliximab (Remicade) and adalimumab (Humira), both monoclonal antibodies towards TNF-α, are widely used in the treatment of Crohn's disease and ulcerative colitis. Loss of efficacy, infusion and injection-site reactions and hypersensitivity reactions have been described due to the development of antibodies towards these agents.2 We agree with Ben-Horin et al that the interpretation of ATI with TLI is important to document the clinical response of a patient to infliximab. However, we urge that these measurements are performed early in the treatment. Previously it was stated that the TLI measured early after …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • PostScript
    Shomron Ben-Horin Yehuda Chowers